Share-based Payment Arrangement, Expense of Icosavax, Inc. from 30 Jun 2020 to 30 Sep 2023
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Summary
-
Icosavax, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2023.
- Icosavax, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2023 was $6,602,000, a 21% increase year-over-year.
- Icosavax, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2023 was $25,071,000, a 30% increase year-over-year.
- Icosavax, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21,694,000, a 25% decline from 2021.
- Icosavax, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $29,031,000, a 11196% increase from 2020.
- Source SEC data
- View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Icosavax, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2023 | $25,071,000 | $6,602,000 | +$1,168,000 | +21% | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 14 Nov 2023 | 2023 | Q3 |
| Q2 2023 | $23,903,000 | $6,311,000 | +$759,000 | +14% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 14 Aug 2023 | 2023 | Q2 |
| Q1 2023 | $23,144,000 | $6,000,000 | +$1,450,000 | +32% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 10 May 2023 | 2023 | Q1 |
| Q4 2022 | $21,694,000 | $6,158,000 | +$2,481,000 | +67% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 30 Mar 2023 | 2022 | Q4 |
| Q3 2022 | $19,213,000 | $5,434,000 | -$18,236,000 | -77% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 14 Nov 2023 | 2023 | Q3 |
| Q2 2022 | $37,449,000 | $5,552,000 | +$4,144,000 | +294% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 14 Aug 2023 | 2023 | Q2 |
| Q1 2022 | $33,305,000 | $4,550,000 | +$4,274,000 | +1549% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 10 May 2023 | 2023 | Q1 |
| Q4 2021 | $29,031,000 | $3,677,000 | 01 Oct 2021 | 31 Dec 2021 | 10-K | 30 Mar 2023 | 2022 | Q4 | ||
| Q3 2021 | $23,670,000 | +$23,600,000 | +33714% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 14 Nov 2022 | 2022 | Q3 | |
| Q2 2021 | $1,408,000 | +$1,345,000 | +2135% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 15 Aug 2022 | 2022 | Q2 | |
| Q1 2021 | $276,000 | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 16 May 2022 | 2022 | Q1 | |||
| Q3 2020 | $70,000 | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 15 Nov 2021 | 2021 | Q3 | |||
| Q2 2020 | $63,000 | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 13 Sep 2021 | 2021 | Q2 |
Icosavax, Inc. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $21,694,000 | -$7,337,000 | -25% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 30 Mar 2023 | 2022 | FY |
| 2021 | $29,031,000 | +$28,774,000 | +11196% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 30 Mar 2023 | 2022 | FY |
| 2020 | $257,000 | 01 Jan 2020 | 31 Dec 2020 | 10-K | 30 Mar 2022 | 2021 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.